Vertex Pharmaceuticals Inc. (VRTX) announced positive results from a viral kinetic study of the nucleotide analogue ALS-2200 after the bell Monday, for the treatment of hepatitis C. There was a median 4.54 log10 reduction in hepatitis C virus RNA in people with genotype 1 chronic hepatitis C who were new to treatment after seven days of dosing with 200 mg of ALS-2200 once daily.
The company also reported second quarter non-GAAP net income of $0.46 per share, which fell short of the consensus estimate of $0.59.
Vertex Pharmaceuticals was range-bound for the majority of Monday's session and closed up by 0.64 at $49.96. The stock finished near the upper end of a one-week range. Vertex is now up 3.79 on 113K shares after the bell.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.